Kenneth J. O’Byrne
Translational Research Institute(AU)The Royal Melbourne Hospital(AU)Queensland University of Technology(AU)The University of Queensland(AU)Greenslopes Private Hospital(AU)Princess Alexandra Hospital(AU)Princess Alexandra Hospital(AU)Centre for Cancer Biology(AU)Princess Alexandra Hospital(GB)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Cancer Immunotherapy and Biomarkers, Lung Cancer Research Studies, Cancer Genomics and Diagnostics, Lung Cancer Diagnosis and Treatment
Most-Cited Works
- → Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer(2013)3,388 cited
- → Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations(2013)3,181 cited
- → Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden(2018)3,112 cited
- → Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer(2019)2,789 cited
- → Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.(2005)1,597 cited
- → Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials